Fig 1: Specific Bromodomain-containing proteins are recruited to the 9q12 locus in stressed HeLa cells. Bromodomain containing proteins (green signals) are co-detected with HSF1 (red signals) by immunofluorescence on stressed cells. Endogenous BRD2, BRD3 and BRD4 are enriched at nSBs together with endogenous HSF1 (green signals) while TAF250 and ATAD2 are not. Absence of TAF1 and ATAD2 enrichment at the 9q12 locus was confirmed by comparative analysis of TAF1 or ATAD2 and HSF1 fluorescence profiles. Scale bar = 5 µm.
Fig 2: Effect of different H2O2 concentrations on the Keap1-Nrf2 signalling pathway in NPMSCs. a and b Western blotting analysis of Keap1 and Nrf2 expression in NPMSCs exposed to different concentrations of H2O2 (n = 3, *P < 0.05, **P < 0.01, one-way ANOVA followed by Bonferroni’s post hoc test. #P < 0.05 compared to the 300 μM H2O2 group). c and d Western blotting analysis of Brd4 expression in NPMSCs exposed to different concentrations of H2O2 (n = 3, *P < 0.05, **P < 0.01, one-way ANOVA followed by Bonferroni’s post hoc test. #P < 0.01 compared to the 300 μM H2O2 group). e and f Western blotting analysis estimating the effect of 75 μM H2O2 pretreatment on Keap1, Nrf2, and Brd4 expression and quantification when NPMSCs were subsequently exposed to 300 μM H2O2 (n = 3, *P < 0.05, **P < 0.01, one-way ANOVA followed by Bonferroni’s post hoc test. ##P < 0.01 compared to the 300 μM H2O2 group)
Fig 3: Expression of BRD4 in OGD-treated H9C2 cells and the effect of shBRD4 on OGD-induced cell damage. A, mRNA and protein levels of BRD4 in OGD-treated H9C2 cells. B, Effect of shBRD4 on the activity of cardiac enzymes. *P < 0.05 versus OGD group; †P < 0.05 versus OGD + shCtrl group. n = 9 independent samples per group.
Fig 4: BRD4 is critical for the anti-cell growth effects of GA on ATC cells. SW1736 and KAT-18 cells transfected with BRD4 overexpression plasmid or control vector, were treated with 2 µg/ml for 48 h, the protein expression of BRD4, Bcl-2 and Bax was determined using western blotting (A and B). (C and D) Cell viability was determined via CCK-8 assay at indicated time points. (E and F) Colony formation assay showed that BRD4 overexpression significantly rescue the inhibitory effects of GA on ATC cells. (G and H) Overexpression of BRD4 could partially counteract the suppressing cell apoptosis. *P<0.05. GA, gambogic acid; ATC, anaplastic thyroid cancer; BRD4, bromodomain-containing protein 4.
Fig 5: BRD4 regulates HMOX1 over the SP1-binding motif. (a) Mapping of the BRD4 activating region on the HMOX1 promoter. BRD4 (pcDNA-BRD4-FL) or empty vector (EV) were co-transfected with a luciferase construct carrying the full-length HMOX1 promoter (HMOX1-WT), a 367-bp long (HMOX1-367) or a 228-bp (HMOX1-228) long fragment of the HMOX1 promoter. Twenty-four hours post transfection, the cells were harvested, and the promoter activity was determined and normalized to the renilla luciferase and the EV signals. The results represent the averages of three independent experiments (*P-values<0.05 according to two-tailed t-tests). (b) MEME analyses of BRD4 ChIP-Seq data. The binding matrix represents the identified BRD4 ‘binding motif' of the ChIP-Sequencing. Using the TOMTOM analysis tool, the SP1-binding motif was identified as one of the top known binding motifs associated with the BRD4-binding site (P-value: 0.00026, E-value: 0.2305; q-value: 0.1024). At the right, the SP1-binding site in the HMOX1 promoter (HMOX1-WT) and the used mutation (HMOX1-SP1-mut) are shown. (c) Reporter assays with wild-type (HMOX1-WT) or SP1-site-mutated (HMOX1-SP1-mut) HMOX1 reporter constructs. BRD4 and SP1 (pTL-FlagC-SP1) expressing constructs were co-transfected with either the HMOX1 wild-type promoter or with the SP1-binding site mutant. Twenty-four hours post transfection, the cells were harvested, and the promoter activity was determined and normalized to the renilla luciferase signal. The results represent the average of two independent experiments (*P-values<0.05 according to two-tailed t-tests)
Supplier Page from Abcam for Anti-Brd4 antibody